Evidence map›Paper›PMID 11122856›Full record

ReviewCurrent oncology reports2000

Vaccination for melanoma.

L W Thompson, L Brinckerhoff, C L Slingluff

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current oncology reports, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Anal melanoma.Clinics in colon and rectal surgery · 2006
    Article
  2. Early stage (I, II, III) melanoma.Current treatment options in oncology · 2001
    Review
  3. Reducing primary melanoma mortality.Current oncology reports · 2000
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

L W ThompsonDepartment of Surgery, University of Virginia Health Science Center, PO Box 10005, Charlottesville, VA 22906-0005, USA.
L Brinckerhoff
C L Slingluff

Funding

MELANOMA VACCINES USING MHC-ASSOCIATED PEPTIDESR01CA057653 · NCI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI SLINGLUFF, CRAIG LEE · 1997 to 2012
$3.4M
HLA-A2 ASSOCIATED PEPTIDE EPITOPES FOR CTL ON MELANOMAR29CA057653 · NCI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI SLINGLUFF, CRAIG LEE · 1992 to 1996
–
NCI NIH HHS CA57653
6 · The paper itself

Abstract

Our knowledge of the immune system has grown tremendously in the 50 years since Coley used bacteria in an attempt to create a vaccine for cancer. The strategy for cancer vaccines has developed in that time as well. Both clinical and laboratory evidence suggests that melanoma is the more immunogenic of solid tumors. If treated early, melanoma can be controlled with surgery, but many patients continue to die from it. With our increased understanding of the immune system's interaction with melanoma, many clinical trials of melanoma vaccines are now underway. Vaccines designed to treat metastatic melanoma have shown some evidence of clinical effectiveness. This article outlines the current status of melanoma vaccination.

Indexed as

VaccinationAntigens, NeoplasmCancer VaccinesCytokinesDendritic CellsHumansImmunity, CellularMelanomaNeoplasm MetastasisNeoplasm ProteinsT-LymphocytesAntigens, NeoplasmCancer VaccinesCytokinesNeoplasm Proteins

Identifiers

PMID11122856

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.